Last updated on February 2019

A Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Brief description of study

This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence

Clinical Study Identifier: NCT03383458

Contact Investigators or Research Sites near you

Start Over

Site 0057

Local Institution
Bondy, France
  Connect »

Site 0061

Local Institution
Creteil Cedex, France
  Connect »

Site 0054

Local Institution
Paris, France
  Connect »

Site 0046

Local Institution
Clichy, France
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.